Form 4: BioAge Labs Director Receives Stock Option Grant
Director Equity Grant
Director Vijay Satyanand Pande was granted 22,000 stock options in BioAge Labs, Inc. as part of a standard equity compensation arrangement.
Summary
- Director Vijay Satyanand Pande received a grant of 22,000 stock options on June 10, 2026.
- The options have an exercise price of $15.48 per share.
- The options are set to expire on June 9, 2036.
- Vesting occurs on the earlier of the next annual stockholder meeting or the one-year anniversary of the grant date.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- The grant results in potential future dilution for existing shareholders upon exercise.
Risks
- Market volatility could impact the value of the options relative to the exercise price.
Future Outlook
The options vest based on continued service, aligning the director's tenure with the company's upcoming annual meeting or the one-year anniversary of the grant.
Management Comments
- No specific management commentary provided in this regulatory filing.
Industry Context
StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain high-caliber scientific and academic leadership.
Comparison to Industry Standards
- The grant size and vesting schedule are consistent with typical director compensation packages for mid-cap biotechnology firms.
- The use of a one-year cliff or annual meeting vesting is a standard governance practice to ensure director commitment.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of 22,000 stock options to Director Vijay Satyanand Pande. | 06/10/2026 | Standard alignment of director incentives with company performance. |
Stakeholder Impact
- Shareholders may experience minor dilution if these options are exercised in the future.
Next Steps
- Vesting of options upon the earlier of the next annual meeting or June 10, 2027.
Key Dates
| Date | Description |
|---|---|
| 06/10/2026 | Date of the stock option grant transaction. |
| 06/12/2026 | Date the Form 4 was filed with the SEC. |
| 06/09/2036 | Expiration date of the granted stock options. |
Keywords
BioAge Labs, BIOA, Director Compensation, Stock Options, Insider Transaction, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.